The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A phase III trial-in-progress called REPLATINUM that compares RRx-001 + a platinum doublet to a platinum doublet in third-line or beyond small cell lung cancer.

Daniel  Morgensztern

Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; PharmaMar; Takeda

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst)

Chao Hui  Huang

Stock and Other Ownership Interests  - Vanguard Funds

Honoraria - Ipsen

Consulting or Advisory Role - Biodesix; Ipsen

Research Funding - Bayer (Inst); Benta Pharma Industries (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Novartis (Inst)

Christian Diego  Rolfo

Consulting or Advisory Role - Mylan

Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Guardant Health; MSD; Novartis

Travel, Accommodations, Expenses - AstraZeneca

(OPTIONAL) Uncompensated Relationships - Biomark (Inst); OncoDNA

John C.  Ruckdeschel

Leadership - Genyous/Omnitura; Real Time Micro Spectroscopy

Stock and Other Ownership Interests  - Genyous/Omnitura; Genyous/Omnitura; Real Time Micro Spectroscopy

Research Funding - EpicentRx; Novartis; Pfizer

Konstantin H.  Dragnev

Research Funding - G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); PharmaMar (Inst); Roche/Genentech (Inst)

Raid  Aljumaily

Consulting or Advisory Role - AstraZeneca; Regeneron

Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)

Ralph J.  Hauke

Stock and Other Ownership Interests  - Aethlon

Honoraria - Best Doctors, Inc

Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); SOTIO (Inst); US Oncology (Inst)

Other Relationship - ABIM Subspecialty Board

Tarek  Mekhail

Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck

Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck

Mary J.  Fidler

Honoraria - AstraZeneca

Consulting or Advisory Role - Abbvie (I); AstraZeneca; Genentech; Genentech (I); Guardant Health; Guardant Health; Rakuten Medical (Inst)

Speakers' Bureau - Genentech; Merck

Research Funding - AstraZeneca (Inst); Biodesix; CytomX Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer/EMD Serono; Rakuten Medical (Inst)

John Turner  Hamm

Honoraria - BrightPath Biotheraputics; Exelixis; Puma Biotechnology

Consulting or Advisory Role - Meda Pharmaceuticals; Pfizer

Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); BrightPath Biotheraputics (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dana-Farber Cancer Institute (Inst); Deciphera (Inst); EMD Serono (Inst); EpicentRx (Inst); Exact Sciences (Inst); Five Prime Therapeutics (Inst); G1 Therapeutics (Inst); GBG Forschungs (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Halozyme (Inst); Immunicum (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Moffitt (Inst); National Surgical Adjuvant Breast and Bowel Project (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Pronova (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); SWOG (Inst)

Alberto  Chiappori

Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer

Speakers' Bureau - Celgene; Genentech; Merck; Novartis; Takeda

Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis